BRPI0714212B8 - método de produzir uma glicoproteína em uma cultura celular - Google Patents

método de produzir uma glicoproteína em uma cultura celular

Info

Publication number
BRPI0714212B8
BRPI0714212B8 BRPI0714212A BRPI0714212A BRPI0714212B8 BR PI0714212 B8 BRPI0714212 B8 BR PI0714212B8 BR PI0714212 A BRPI0714212 A BR PI0714212A BR PI0714212 A BRPI0714212 A BR PI0714212A BR PI0714212 B8 BRPI0714212 B8 BR PI0714212B8
Authority
BR
Brazil
Prior art keywords
glycoprotein
cell culture
producing
present
glycosylation pattern
Prior art date
Application number
BRPI0714212A
Other languages
English (en)
Inventor
Lasko Daniel
M Koza Stephan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38645762&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0714212(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0714212A2 publication Critical patent/BRPI0714212A2/pt
Publication of BRPI0714212B1 publication Critical patent/BRPI0714212B1/pt
Publication of BRPI0714212B8 publication Critical patent/BRPI0714212B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Abstract

método de produzir uma glicoproteína em uma cultura celular, meio de cultura celular e glicoproteína. a presente invenção refere-se a um sistema melhorado para a produção em grande escala de glicoproteínas em cultura celular que é fornecido. de acordo com a presente invenção, células que expressam uma glicoproteína são cultivadas em meios que contém manganês em uma concentração entre aproximadamente 10 e 60 nm. o uso de um tal sistema permite a produção de uma glicoproteína com um padrão de glicosilação aumentado e/ou um padrão de glicosilação que reflete mais exatamente o padrão de glicosilação da glicoproteína que ocorre naturalmente. uma glicoproteína expressa de acordo com a presente invenção pode ser vantajosamente usada na preparação de composições farmacêuticas.
BRPI0714212A 2006-07-13 2007-07-11 método de produzir uma glicoproteína em uma cultura celular BRPI0714212B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83065806P 2006-07-13 2006-07-13
US60/830,658 2006-07-13
PCT/US2007/015767 WO2008008360A1 (en) 2006-07-13 2007-07-11 Production of glycoproteins

Publications (3)

Publication Number Publication Date
BRPI0714212A2 BRPI0714212A2 (pt) 2013-03-26
BRPI0714212B1 BRPI0714212B1 (pt) 2021-01-19
BRPI0714212B8 true BRPI0714212B8 (pt) 2021-05-25

Family

ID=38645762

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0714212A BRPI0714212B8 (pt) 2006-07-13 2007-07-11 método de produzir uma glicoproteína em uma cultura celular

Country Status (23)

Country Link
US (1) US8129145B2 (pt)
EP (3) EP3255141B1 (pt)
JP (1) JP5401310B2 (pt)
KR (1) KR101495549B1 (pt)
CN (2) CN101541950A (pt)
AR (1) AR061976A1 (pt)
AU (1) AU2007272957B2 (pt)
BR (1) BRPI0714212B8 (pt)
CA (1) CA2657248C (pt)
DK (3) DK3255141T3 (pt)
ES (2) ES2440487T3 (pt)
HK (1) HK1214307A1 (pt)
HU (1) HUE039128T2 (pt)
IL (1) IL196252A (pt)
MX (1) MX2009000349A (pt)
PE (1) PE20081194A1 (pt)
PL (2) PL2041270T3 (pt)
PT (2) PT2495307T (pt)
RU (1) RU2463345C2 (pt)
SI (1) SI2495307T1 (pt)
TR (1) TR201807021T4 (pt)
TW (1) TW200812577A (pt)
WO (1) WO2008008360A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
CN101541950A (zh) 2006-07-13 2009-09-23 惠氏公司 糖蛋白的产生
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
MX2009004519A (es) * 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
DK2115126T3 (en) * 2007-03-02 2015-05-04 Wyeth Llc Use of copper and glutamate in cell culture for the preparation of polypeptides
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20090233334A1 (en) * 2008-03-11 2009-09-17 Excellgene Sa Cell cultivation and production of recombinant proteins by means of an orbital shake bioreactor system with disposable bags at the 1,500 liter scale
NZ592097A (en) 2008-10-20 2013-01-25 Abbott Lab Viral inactivation during purification of il-12 and il-18 antibodies
CA2911256A1 (en) 2008-10-20 2010-12-09 Robert K. Hickman Isolation and purification of antibodies using protein a affinity chromatography
EP2456871B1 (en) * 2009-07-24 2016-09-07 Dr. Reddy's Laboratories, Ltd. Production of erythropoiesis stimulating protein using metal ions
ES2668079T3 (es) * 2009-07-28 2018-05-16 Shire Human Genetic Therapies Composiciones y métodos para tratar la enfermedad de Gaucher
PL3330370T3 (pl) 2010-04-26 2021-09-20 Novartis Ag Sposób hodowania komórek cho
RU2615448C2 (ru) * 2010-12-28 2017-04-04 Чугаи Сейяку Кабусики Кайся Описание способа культивирования животной клетки
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
MY169935A (en) 2011-04-29 2019-06-18 Biocon Biologics India Ltd "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof"
AU2012283858C1 (en) 2011-07-20 2020-01-23 Zepteon, Incorporated Polypeptide separation methods
WO2013114245A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014170866A2 (en) * 2013-04-18 2014-10-23 Dr. Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased galactosylation content
BR112016002622B1 (pt) * 2013-08-20 2023-04-11 Lek Pharmaceuticals D.D Meio de cultura celular e uso de selênio
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10590455B2 (en) * 2014-02-25 2020-03-17 Dr. Reddy's Laboratories Limited Process for modifying galactosylation and G0F content of a glycoprotein composition by glutamine supplementation
RU2712562C2 (ru) * 2014-02-27 2020-01-29 Ф.Хоффманн-Ля Рош Аг Модулирование клеточного роста и гликозилирования при производстве рекомбинантных гликопротеинов
WO2016089919A1 (en) 2014-12-01 2016-06-09 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
EP3042952A1 (en) * 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
RU2017145002A (ru) 2015-05-22 2019-06-24 Цсл Беринг Ленгнау Аг Способы получения модифицированного фактора фон виллебранда
WO2016196621A1 (en) 2015-06-01 2016-12-08 Biogen Ma Inc. Manganese supplementation for control of glycosylation in mammalian cell culture process
CN104894055B (zh) * 2015-06-15 2018-07-17 成都金凯生物技术有限公司 一种优化的细胞培养基、细胞培养方法及其在制备蛋白和抗体中的应用
KR101932137B1 (ko) * 2017-01-02 2018-12-24 연세대학교 산학협력단 당화 증강용 조성물 및 당화 증강된 단백질의 제조방법
WO2018210771A1 (en) 2017-05-17 2018-11-22 Octapharma Ag Method for the production of a recombinant target protein
HUP1800376A2 (hu) * 2018-11-07 2020-05-28 Richter Gedeon Nyrt Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
CN114206924A (zh) 2019-12-06 2022-03-18 瑞泽恩制药公司 抗vegf蛋白组合物及其制备方法
US20240150723A1 (en) * 2021-03-23 2024-05-09 Biogen Ma Inc. Reducing host cell impurities during recombinant protein production

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NO162160C (no) 1987-01-09 1989-11-15 Medi Cult As Serumfritt vekstmedium, samt anvendelse derav.
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
SU1587450A1 (ru) * 1988-05-04 1990-08-23 Институт биоорганической химии АН БССР Способ разделени гликозилированной и негликозилированной форм пролактина биологического материала
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
US5156964A (en) 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5118816A (en) 1990-12-26 1992-06-02 American Cyanamid Company 2-aryl-5-(trifluoromethyl)-2-pyrroline compounds useful in the manufacture of insecticidal, nematocidal and acaricidal arylpyrroles
DE69233774D1 (de) 1991-01-21 2009-12-10 Elan Pharm Inc Prüfung und Modell für Alzheimers-Krankheit
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DK1087013T3 (da) 1992-08-21 2009-05-11 Univ Bruxelles Immunoglobuliner uden lette kæder
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
CA2745736C (en) 1996-10-23 2016-11-22 The Trustees Of The University Of Pennsylvania Immunotherapy and improved vaccines
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
AU2113199A (en) 1998-01-12 1999-07-26 Betagene, Inc. Media for neuroendocrine cells
BR9908267A (pt) 1998-02-27 2000-10-24 Univ Pennsylvania Plasmìdeo, composição farmacêutica, processos para induzir uma resposta imunológica em um indivìduo contra um imunógeno, para imunizar um indivìduo contra uma infecção por vìrus de herpes simples e para tratar um indivìduo que tem uma doença autoimune, vacina recombinante, e, patógeno atenuado vivo
DE69937571T2 (de) 1998-09-30 2008-09-04 The Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutiertes cholera holotoxin als hilfsmittel
EP1171615B1 (en) * 1999-04-26 2006-12-13 Genentech, Inc. Cell culture process for glycoproteins
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
EE200200538A (et) 2000-03-22 2004-04-15 Octagene Gmbh Rekombinantsete verehüübimisfaktorite produtseerimine inimese rakuliinides
US20040001822A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
IL159209A0 (en) 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
AU2002346249B2 (en) 2001-06-07 2007-03-15 The Regents Of The University Of Colorado Mutant Forms of Cholera Holotoxin as an Adjuvant
LT1507556T (lt) 2002-05-02 2016-10-10 Wyeth Holdings Llc Kalicheamicino darinio ir nešiklio konjugatai
AU2003249055B2 (en) 2002-07-15 2008-06-26 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
PE20070796A1 (es) 2005-10-24 2007-08-15 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
EP1943333A2 (en) * 2005-11-02 2008-07-16 Wyeth a Corporation of the State of Delaware Methods for adapting mammalian cells
CA2630811C (en) * 2005-12-08 2016-05-31 Amgen Inc. Improved production of glycoproteins using manganese
CN101541950A (zh) 2006-07-13 2009-09-23 惠氏公司 糖蛋白的产生

Also Published As

Publication number Publication date
DK3255141T3 (da) 2022-01-31
US8129145B2 (en) 2012-03-06
PE20081194A1 (es) 2008-09-22
EP2041270A1 (en) 2009-04-01
ES2668212T9 (es) 2018-05-30
EP2495307A1 (en) 2012-09-05
MX2009000349A (es) 2009-03-09
CN104878064A (zh) 2015-09-02
EP2041270B1 (en) 2013-11-20
DK2041270T3 (da) 2014-01-27
IL196252A0 (en) 2011-08-01
EP3255141A1 (en) 2017-12-13
PT2495307T (pt) 2018-05-10
KR101495549B1 (ko) 2015-02-25
EP3255141B1 (en) 2021-12-01
PL2041270T3 (pl) 2014-04-30
CA2657248C (en) 2018-10-30
ES2668212T3 (es) 2018-05-17
DK2495307T5 (en) 2018-07-16
AU2007272957A1 (en) 2008-01-17
HK1214307A1 (zh) 2016-07-22
TR201807021T4 (tr) 2018-06-21
HUE039128T2 (hu) 2018-12-28
BRPI0714212A2 (pt) 2013-03-26
AR061976A1 (es) 2008-08-10
JP2009543550A (ja) 2009-12-10
SI2495307T1 (en) 2018-05-31
CA2657248A1 (en) 2008-01-17
EP2495307B9 (en) 2018-05-02
BRPI0714212B1 (pt) 2021-01-19
JP5401310B2 (ja) 2014-01-29
RU2463345C2 (ru) 2012-10-10
DK2495307T3 (en) 2018-05-07
WO2008008360A1 (en) 2008-01-17
PT2041270E (pt) 2013-12-27
IL196252A (en) 2016-02-29
US20080081356A1 (en) 2008-04-03
RU2008152449A (ru) 2010-08-20
EP2495307B1 (en) 2018-02-21
TW200812577A (en) 2008-03-16
AU2007272957B2 (en) 2014-05-01
KR20090029841A (ko) 2009-03-23
ES2440487T3 (es) 2014-01-29
PL2495307T3 (pl) 2018-07-31
CN101541950A (zh) 2009-09-23

Similar Documents

Publication Publication Date Title
BRPI0714212B8 (pt) método de produzir uma glicoproteína em uma cultura celular
BRPI0514694A (pt) produção de proteìna de fusão tnfr-ig
WO2008006038A3 (en) Methods and compositions for butanol production
WO2009023525A3 (en) Methods of modulating mesenchymal stem cell differentiation
BR112012011711A2 (pt) Variantes de beta-glucosidase 1 (bgl1) com propriedades otimizadas, seu método de produção, composição, ácido nucleico, vetor de expressão, célula hospedeira, bem como método de conversão de biomassa em açúcares
NO20074278L (no) Tigecyklinblandinger og fremgangsmater for fremstilling
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
CA2816976A1 (en) Optogenetic control of reward-related behaviors
JP2008500279A5 (pt)
EA201270224A1 (ru) Среда для культивирования клеток для экспрессии белков adamts
BR112012003560A8 (pt) bebida alcoólica, método de produção de uma bebida alcoólica e composição farmacêutica
DOP2006000049A (es) Formas farmaceuticas con propiedades farmacocineticas mejoradas
BR112012032208A2 (pt) fermentação de biomassa
MX341988B (es) Glicosilacion tipo mamifera en plantas para la expresion de glicosil-transferasas no mamiferas.
BR112014032544A2 (pt) método para produzir iduronato-2-sulfatase recombinante
BR112014031220A2 (pt) estrutura de eletrodo com capacidade de respiração e método e sistema para uso em separação da água
BR112013033448A2 (pt) células deficientes em ácido cmp-n-acetilneuramínico hidroxilase e/ou glicoproteína alfa-1,3-galactosiltransferase
BR112015021993A8 (pt) polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular
BR112014028956A2 (pt) processos para fermentar gás de síntese e para reduzir a condutividade em fermentação e meio de fermentação
BR112012029271A2 (pt) fungo isolado, método para produzir e kit para fabricar pelo menos um composto selecionado do grupo que consite de 1, 8-cineol, 1-metil-1,4-cicloexadieno, e (+) -a-metileno-a-fenchocanforona, molécula de ácido nucleico isolada de um fungo,e, método para gerar cepas mutantes de um fungo.
BRPI0518853A2 (pt) estabilizaÇço de Ésteres de glicocorticàides com Ácidos
WO2012142094A3 (en) Compositions and methods for increased ethanol production from biomass
ATE473752T1 (de) Verwendung von verbindungen zur induktion der synthese von sirt-proteinen bei der oder für die herstellung eines kosmetikums oder einer pharmazeutischen zusammensetzung
MX358639B (es) Sistema de mantenimiento para células reproductoras.
EP2341147A3 (en) Preprimitive streak and mesendoderm cells

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/07/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.